Prescient Therapeutics Leads ASX200 Biotech Push With Innovations in Cancer Therapy (ASX:PTX)
PTX-100 targets high-mortality cancers linked to RAS mutations.
PTX-100 targets high-mortality cancers linked to RAS mutations.
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is aiming to establish new frontiers in cancer care, with...
The first patient has been dosed in Prescient Therapeutics Phase 2a clinical trial of PTX-100...
Prescient Therapeutics (ASX: PTX) begins Phase 2A trial of PTX-100 for rare lymphoma, drug shows...
Prescient Therapeutics (ASX: PTX) earlier this week began its Phase 2A clinical trial of PTX-100...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the initiation of a Phase...
Prescient Therapeutics: Shareholder Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics Ltd has kicked off its Phase 2a clinical trial evaluating PTX-100 for relapsed...
Prescient Therapeutics (ASX: PTX) has received fast-track designation from the US Food and Drug Administration...
Prescient Therapeutics Ltd has received Fast Track Designation from the United States Food and Drug...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.